Fabry Disease Epidemiology Forecast 2025-2034

Fabry disease, also known as Anderson-Fabry disease, is a rare, inherited genetic disease that causes the buildup of globotriaosylceramide (a type of fat) in the body's cells. The prevalence of Fabry disease is estimated to be 1-5 per 10,000 individuals. Studies show that this lysosomal storage disease's milder, late-onset forms are more prevalent than the classic, severe form.

Fabry Disease Epidemiology Forecast Report Coverage

The “Fabry Disease Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Fabry disease. It projects the future incidence and prevalence rates of Fabry disease across various populations. The study covers age and type as major determinants of the Fabry disease-affected population. The report highlights patterns in the prevalence of Fabry disease over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Fabry disease in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Fabry Disease: Disease Overview

Fabry disease (alpha-galactosidase-A deficiency or Anderson-Fabry disease) belongs to a group of conditions called lysosomal storage diseases. It causes the buildup of fatty material in the cells of the body, resulting in cell dysfunction and complications such as stroke, progressive kidney damage, and heart failure. Common symptoms include dark red spots on the skin (angiokeratomas), pain in the feet and hands, hearing loss, and fever, among others.

Fabry Disease: Treatment Overview

There is no approved treatment for Fabry disease, but there are certain therapies that can prevent the disease from progressing. Enzyme replacement therapy is a common treatment option, which includes the intravenous infusion of a synthetic alpha-GAL enzyme every two weeks. Oral chaperone therapy is also used for patients over 16 years of age. It helps in correcting the folding of a mutated alpha-Gal A found in Fabry disease patients.

Epidemiology

The Fabry disease epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for Fabry disease by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Fabry disease and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• The prevalence of Fabry disease is reported to be 1 per 40,000 individuals, with the prevalence in Caucasians going as high as 1 per 17,000 individuals.
• Approximately 1 in 1,000 to 9,000 individuals are affected by Fabry disease, with the milder, late-onset forms of the condition more prevalent in comparison to the classic, severe form.
• According to the Orphanet, the prevalence of Fabry disease ranges from 1 to 5 in 10,000 people.
• As per a study published in the BMC Nephrology (2022), the overall prevalence of Fabry disease in chronic kidney disease (CKD) patients on hemodialysis was estimated to be about 0.2%.

Country-wise Fabry Disease Epidemiology

The Fabry disease epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of Fabry disease varies significantly between countries due to differences in genetic prevalence, diagnostic practices, healthcare infrastructure, and access to specialized treatment options. According to the National Institutes of Health Genetics Home Reference, the United States estimates of Fabry disease are estimated to be 1 in 40,000 to 60,000 males.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Fabry disease based on several factors.
• Fabry Disease Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of Fabry disease are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of Fabry disease epidemiology in the 8 major markets?
• What will be the total number of patients with Fabry disease across the 8 major markets during the forecast period?
• What was the country-wise prevalence of Fabry disease in the 8 major markets in the historical period?
• Which country will have the highest number of Fabry disease patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of Fabry disease during the forecast period of 2025-2034?
• What are the currently available treatments for Fabry disease?
• What are the disease risks, signs, symptoms, and unmet needs of Fabry disease?

This product will be delivered within 3-5 business days.